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ABSTRACT
In the current pandemic, the highly contagious nature of the severe acute 
respiratory syndrome coronavirus type 2 (SARS-CoV-2) leads to an enormous 
burden for the global health care system and creates challenging socioeconomic 
problems. Respiratory mucosa, the main entrance of SARS-CoV-2 infection, are 
equipped with an innate immune defense system as the initial response against 
infection. Activation of the adaptive immune system facilitates viral clearance 
as well as providing immunological memory for prevention from subsequent 
exposure. However, despite repeated efforts at implementing appropriate 
interventions, severe and fatal cases are continuing to occur and reports of 
recurrent cases need clarification. Host factors may contribute to the severity 
of the diseases while viral immune evasion is a common phenomenon leading 
to severe outcomes and recurrent infection. Discussions of immunological-
based tests for screening, herd immunity, along with the possible advantages 
or potentially futile efforts of development of vaccine and alternative 
immunotherapy have become a part of daily household conversations. In this 
review, evidence of innate and adaptive immune responses or lack of them, 
and immunological problems relevant for SARS-CoV-2 will be summarized. 
Finally, perspectives for future studies especially in the Indonesian population 
will be sketched.
ABSTRAK
Pandemi severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) 
yang sangat menular menyebabkan beban pada system pelayanan kesehatan 
dan masalah social ekonomi di seluruh dunia. Mucosa tractus respiratorius, 
pintu masuk utama infeksi SARS-CoV-2, dilengkapi dengan system imun bawaan 
sebagai respon awal infeksi. Pengaktifan system imun adaptif memfasilitasi 
pembersihan virus serta menghasilkan memori imun sebagai pencegahan 
untuk infeksi berikutnya. Sebagian besar orang yang terinfeksi sembuh namun 
kasus yang parah dan fatal serta kasus infeksi berulang juga ditemukan. 
Faktor inang berkontribusi terhadap keparahan penyakit. Penghindaran 
virus dari system imun adalah fenomena umum yang juga mengarah pada 
manifestasi klinis yang parah dan infeksi berulang. Diskusi tentang pencarian 
kasus positif terinfeksi SARS-CoV-2 dengan deteksi antibodi, kekebalan 
kawanan, kemungkinan keberhasilan atau kegagalan pengembangan vaksin 
dan pengembangan terapi imunologi menjadi pembicaraan sehari-hari 
di masyarakat. Dalam telaah ini, bukti atau kurangnya bukti respon imun 
bawaan dan adaptif dan masalah imunologis yang relevan untuk infeksi 
SARS-CoV-2 akan dirangkum. Pada bagian akhir, akan didiskusikan perspektif 
untuk penelitian terkait dengan pandemi SARS-CoV-2 terutama pada populasi 
Indonesia.
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INTRODUCTION
The 21st century has already seen 
two outbreaks of coronaviruses.The first 
on,severe acute respiratory syndrome-
coronavirus (SARS-CoV) in 2002 and 
the second, Middle East respiratory 
syndrome coronavirus (MERS-CoV) in 
2012. Now in 2020 we are in the middle 
of another viral outbreak called severe 
acute respiratory syndrome-coronavirus 
(SARS-CoV-2). The recent emergence 
of SARS-CoV-2 infection started in the 
city of Wuhan in early December 2019, 
hence the disease is called coronavirus 
disease 2019 (COVID-19). The disease 
has now become a global pandemic. 
As of April 28th, 2020the World Health 
Organization (WHO) database recorded 
over 2.9 million confirmed cases globally, 
including over 200,000 deaths in more 
than 200 countries. 
Coronaviruses, the largest 
known positive-sense single-stranded 
ribonucleic acid   (ssRNA) viruses, belong 
to ordo Nidovirales. The family is classified 
into three groups, based on antigenic 
relationships of the spike (S), membrane 
(M) and nucleocapsid (N) proteins and 
further viral genetic phylogeny. SARS-
CoV, MERS-CoV and SARS-CoV-2 are 
classified in one of the groups. As the 
name implies, these viruses cause more 
severe manifestations compared to 
members of the other group.1-3
The virus particle has a spherical 
shape that is 60-140 nm in diameter with 
distinctive spikes about 8 to 12 nm in 
length.4 SARS-CoV-2 genomic sequences 
are closer to those in bats, with 
similarities around 96%. The sequences 
analysis showed that the genome of the 
viruses from different patients are very 
conserved,5,6 suggesting a recent human 
virus. Phylogenetic network analysis 
reported by Forster et al.7 showed 3 
clusters of SARS-CoV-2 based on amino 
acid changes: the A, B, and C clusters. A is 
the ancestral type, B derived from A, and 
further derives into C. Clusters A and C 
are found outside East Asia, while B is 
common in East Asian countries. 
SARS-CoV-2 is transmitted from 
human to human through droplets 
containing the virus particles via the 
mucous membranes of the eyes, mouth 
or nose. However, there are no reports 
on the presence of the viral RNA from 
COVID-19 patients with conjunctivitis. 
Some studies reported virus shed 
from the stool (1-2%) in the late phase 
of infection,8 suggesting multiple 
transmission routes of the virus.9 The 
receptor binding site of SARS-CoV-2 and 
SARS-CoV is similar, with variations in 
some key amino acids.6 Infection of SARS-
CoV-2 to mucosal epithelium depends on 
the binding of S1 protein to the host’s 
angiotensin-converting enzyme (ACE)-2 
protein (FIGURE 1), which is expressed in 
type II pneumocytes among other cells. 
Viral entry requires S protein priming 
by cellular protease, the transmembrane 
protease, serine 2 (TMPRSS2), which 
causes the cleavage of S1/S2 and S2’ sites. 
The virus attachment further allows 
the fusion of virus with the cellular 
membrane. Similar capacity was already 
shown by SARS-CoV,10 but several amino 
acid differences in the S2 protein cause 
more efficient infection capacity of SARS-
CoV-2 compared to the SARS-CoV.11
Compared to the other 2 SARS-related 
coronavirus, SARS-CoV-2 infection results 
in milder symptoms. Three stages of 
SARS-CoV-2 infection are incubation and 
asymptomatic period with or without 
detectable virus, detectable virus with 
common cold and influenza-like illness, 
and variety of SARS such as pneumonia 
with high viral load.12 The first and 
second stages of infection require decent 
immune capacity. Once innate and 
adaptive immune responses breakdown, 
the virus will propagate and massive 
destruction of the affectedtissues will 
occur, especially in organs that have 
high ACE2 expressions such as lungs, 
intestines and kidneys.13As mentioned 
earlier, the virus may enter via several 
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routes other than respiratory tract, e.g. 
digestive tract and olfactory nerves14 
lead to various symptoms.12
The immune system plays an 
important role in eliminating the 
virus, yet it may also be involved in 
the disease pathogenesis that leads to 
severe morbidity and mortality. We are 
aware that the pathogenesis of SARS-
CoV-2 infection may be more complex 
and related to other systems such as 
compromising the function of hemoglobin 
and blood coagulation.15 However, those 
topics are beyond the scope of this 
review. We begin with the main question 
related to what do we know about the 
innate and adaptive immune responses 
to SARS-CoV-2, the host factors that 
affect immune response, the possibility 
of viral immune evasion, and the 
responses of the immune system in fatal 
cases. Then, we conclude with possible 
immunological-based therapeutic and 
prophylactic approaches. Further, we 
would like to briefly discuss the immune 
consequences of the pandemic through 
the perspectives of Indonesian patients’ 
characteristics.
As a novel and very contagious 
human coronavirus that prevents proper 
immediate investigation, reliable data 
on the immune responses against SARS-
CoV-2 are still limited. Most studies were 
speedy reports with limited number of 
patients or case reports. This minireview 
is based on the latest publications 
concerning SARS-CoV-2, in addition to 
the recent knowledge related to SARS-
CoV reports. Some studies using animal 
models infected with coronavirus or 
other virus were included in order to 
explain the possible mechanisms of the 
immunopathogenesis. Despite being 
published in reputable journals, many 
of our recent references (year 2020, in 
particular) may not be peer-reviewed, 
due to the sense of urgency to combat 
SARS-CoV-2 globally. We searched 
our references by several key words, 
including: COVID-19 OR SARS-CoV-2 OR 
SARS-CoV, and immunity* [AND term/ 
specific topic] in PubMed, Google Scholar 
and World Health Organization (WHO) 
databases.
DISCUSSION 
Appropriate innate and adaptive 
immune responses against 
coronavirus in mild cases
Upon coronavirus infection, the 
infected cells detect viral pathogen‐
associated molecular patterns (PAMPs) 
via their pattern recognition receptors 
(PRRs) such as Toll‐like receptors (TLRs) 
(FIGURE 1).16As a single-stranded (ss) 
RNA virus, the principal TLRs that 
recognize coronavirus nucleic acid are 
TLR7 and TLR8. In addition, retinoic-
acid-inducible gene I (RIG‐ I) is also 
able to recognize them. During their 
replication, coronaviruses generate 
double-stranded (ds)RNA intermediates 
which are recognized by melanoma 
differentiation-associated gene 5 
(MDA5).3,16 The recognition of viral 
nucleic acid by PRRs occurs in endosomes, 
endocytolysosomes and cytoplasm.16 
MyD88 acts as an adapter protein by 
most TLRs. Coronavirus infection mainly 
activates the transcription factors such 
as nuclear factor-kappa beta (NF‐κB) 
and mitogen‐activated protein kinases 
(MAPKs) pathways to induce host 
responses such as type I interferon (IFN) 
and inflammatory factors.3 Type I IFN via 
interferon-α/β receptor, in turn, activates 
the JAK-STAT pathway that initiates the 
transcription of IFN-stimulated genes 
under the control of IFN-stimulated 
response elements containing 
promoters.3 As the host’s major antiviral 
molecules, IFNs limit viral spread, and 
play an immunomodulatory role to 
promote macrophage phagocytosis, as 
well as natural killer (NK) cells restriction 
of infected target cells. 
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FIGURE 1. SARS-CoV-2 particle, viral entryand induction of innate immune 
response. Viral spike1 (S1) protein binds tohost’s ACE-2 protein. The 
virus attachment further allows endocytosis of the viral particle. 
Innate immune system detects viral ssRNA viaTLR7 and TLR8, 
further activatestranscription factors such as NF‐κB and MAPKs(not 
drawn) pathways to induce the expression of host’s pro-inflammatory 
cytokines. Virus ssRNA anddouble-stranded (ds)RNA generated as 
intermediate in virus replication, are also recognized by RIG‐I and 
MDA5 which further induce the expression of type I IFN that leads 
to antiviral state, i.e. restricts virus replication and signals the viral 
invasion to adaptive immune system.3,10,16
A successful  accumulation of this type 
I IFN response should be able to suppress 
viral replication and dissemination at an 
early stage.3  However, transmission of 
this virus is reported from asymptomatic 
infected individuals. This situation 
is very likely to occur due to delayed 
early response of the innate immune 
response.17 Later on, the delayed type 
I IFN activation leads to influx of 
neutrophils and monocyte-macrophage 
and induces tissue inflammation and 
development of symptoms. The typical 
symptoms of COVID-19 are fever, cough, 
generalized malaise or myalgia. Some 
patients reported loss of smell and taste 
called anosmia and ageusia due to the 
inflammation  in the olfactory mucosa 
and tongue, respectively. Laboratory 
findings indicated upregulated 
neutrophilia, with increased C-reactive 
protein (CRP) and interleukin-6 (IL-
6).18,19 Some infected individuals remain 
asymptomatic and become silent cases.20
Initiation of adaptive immune 
responses against SARS-related 
coronavirus begins with the activation 
of respiratory dendritic cells (rDCs) after 
engulfing the viral antigen. Furthermore, 
rDCs migrate to the draining (mediastinal 
and cervical) lymph nodes (DLN) and 
present processed antigens to naïve 
T cells. T cells then become activated, 
proliferate and migrate to site of 
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infection (lung).21 Lymphopenia may 
occur as a result of lymphocyte drainage 
into the site of infection. In those cases, 
increases on the neutrophil/lymphocyte 
ratio is reported.18,19
The crucial protective role of T 
cells immune response in coronavirus 
infections has been clearly documented 
in several animal models infected 
with various coronaviruses.22 Cytokine 
microenvironments generated by 
antigen presenting cells direct T cells 
responses.17,22  In general, TH1 orchestrates 
the direction of T cells response followed 
by cytotoxic T  lymphocytes (CTL) that 
are essential in killing viral infected cells. 
Intravenous immunization with peptide-
loaded dendritic cells (DCs) followed by 
intranasal boosting with recombinant 
vaccinia virus (rVV) encoding single 
immunodominant epitope of SARS 
resulted in accumulation of virus-specific 
memory CD8+ T cells in bronchoalveolar 
lavage fluid, lungs, and spleen.23 
Cytotoxic CD8+ T cells account for about 
80% of total infiltrative inflammatory 
cells in the pulmonary interstitium in 
SARS‐CoV‐infected patients and play a 
vital role in elimination of CoV’s infected 
cells.24
Strong evidence showed that 
TH1 response is a key for successful 
control of SARS-CoV and MERS-CoV, 
and probably for SARS-CoV-2 as 
well.17Depletion of CD8+ T cells do not 
affect and delay viral replication at the 
time of infection with SARS‐CoV,21 while 
depletion of CD4+ T cells is associated 
with reduced pulmonary recruitment of 
lymphocytes and neutralizing antibody 
and cytokine production, resulting in 
a strong immune‐mediated interstitial 
pneumonitis and delayed clearance of 
SARS‐CoV from lungs.25
Strong T cells responses are 
significantly correlated with higher 
production of neutralizing antibodies26 
that block the virus from entering 
healthy host cells and protect the host 
against viral re-infection.22 In patients 
infected with coronavirus, specific 
immunoglobulin M (IgM) peaks occur on 
the 9th day after infection. Class switching 
to IgG, assisted by follicular helper T 
cells (TFH cells) can be detected as early 
as 4 days but most of the cases were 
seroconverting at the 2nd week after the 
onset of the disease.27 Delayed and weak 
antibody responses are associated with 
severe outcomes.22
One report of a patient with mild 
symptoms revealed that increased 
plasma cells, TFH cells, activated CD4
+ T 
cells, CD8+ T cells, IgM and IgG antibodies 
that bound to SARS-CoV-2 were detected 
in blood samples before symptomatic 
recovery. These immunological changes 
persisted for at least 7 days following 
full resolution of symptoms.18 From a 
study in Finland, IgM was reported to be 
detected on day 9 and IgG at day 20 after 
infection.28 Specific IgM started to decline 
at week 7.29 Immunoglobulin detection 
was employed as the basis of SARS-CoV 
rapid test. One study in Wuhan reported 
10% SARS-CoV-2 specific IgG positive 
rate from asymptomatic individuals.30
A cohort study of convalescent SARS-
CoV patients from Beijing revealed that 
the concentration of specific serum IgG 
and neutralizing antibodies were highly 
correlated, reaching their peak at 4th 
month after the onset of disease and 
decreasing gradually thereafter. The 
titers decreased noticeably after the 16th 
month, but longlasting specific IgG and 
neutralizing antibodies were reported 
in most of the patients as long as 2 years 
after. Only 11.8% of patients turned to 
negative at month 24.31 In long-term 
follow-up survivors, IgG was detectable 
in recovered patients only up to 6 years 
after SARS-CoV infection,32 suggesting 
decreasing level of memory B cells.32 
Shorter antibody persistence may occur 
due to several factors such as high dose 
corticosteroid treatment that is known to 
suppress antibody response.33
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Coronaviruses immune evasion
Immune evasion is an important 
strategy utilized by pathogens to 
overcome the immune response 
for efficient replication in the host. 
Immune evasion by influenza virus A 
via antigenic shift and antigenic drift 
is a famous phenomenon. As an RNA 
virus, Coronaviruses mutation rates are 
higher than DNA viruses due to higher 
error rate of their RNA polymerases.34 
The high mutation rate leads to higher 
probability for immune evasion in 
secondary exposure.
Coronaviruses have evolved several 
strategies of immune evasion. One 
of the main strategies used by SARS-
CoV to avoid immune detection is by 
shielding its RNA from PRRs. This can 
be done by several mechanisms. One 
approach is by disguising its RNA and 
replication machinery inside replication 
organelles.35 Since concealing its RNA 
and replication machinery is not 
unassailable, SARS-CoV further modifies 
its RNA by adding cap-structure to the 
5’-end or by methylating its mRNA to be 
mediated by SARS-CoV nsp16 protein.36 
Another means is by activating its 
endonuclease, thus destructing its own 
RNA at certain stages of infection to avoid 
the initiation of host’s virus-destroying 
system.37
The other major strategies of immune 
evasion are to restrain the host’s innate 
immune signaling. Coronavirus inhibits 
recognition by PRRs such as TLRs. 
Terminating cellular protein expression 
is one of the effective mechanisms to 
achieve that purpose. SARS-CoV nsp1 
protein arrests the translation process 
by binding to the ribosomal 40S subunit38 
and inducing host’s mRNA degradation.39 
Another mechanism is by manipulating 
stress granules formation. Stress 
granules are structures formed by the 
accumulation of untranslated mRNA as 
a consequence of the arrest of cellular 
translation due to virus infection. 
This accumulation of viral RNA can be 
detected by the host’s immune sensors 
such as Protein Kinase R (PKR), RIG-I, 
and MDA5.40 Other mechanisms of 
suppressing innate immune signaling 
include histone modification,41 
preventing phosphorylation and nuclear 
translocation of IFN-related transcription 
factors such as STAT1.42
To avoid adaptive immune 
responses, coronaviruses inhibit viral 
antigen presentation to T cells. MERS-CoV 
can infect and replicate in macrophages 
and dendritic cells resulting in the 
cells malfunction and inability to 
present antigens to T cells.43 MERS-CoV 
also downregulates MHC I and II in 
macrophages and dendritic cells,44 thus 
leading to failure in activation of naïve 
T cells. MERS-CoV further stimulates T 
cells apoptosis such that lymphopenia 
will ensue.45Deficiency of activated T 
and B lymphocytes are associated with 
persistent infections and lack of virus 
clearance.
Immune system in fatal cases of 
COVID-19
The mortality rate of SARS-CoV-2 
infection is lower compared to the other 
SARS related coronavirus. However, 
due to the highly contagious nature of 
the virus, the number of fatalities is 
higher than the two previous outbreaks 
combined.46 An impaired immune 
response that fails to eliminate the 
virus will likely result in severe cases of 
morbidity and mortality (TABLE 1 and 
2).13 Accordingly, medical researchers 
are asking the important question from 
the immunological point of view: What 
actually drives the unpredictable fatality 
rate of COVID-19? 
In SARS-CoV infections, persistence 
of the viral infection and spreading 
induce activation of macrophages and 
thus, cause increased production of 
pro-inflammatory cytokines that leads 
to consistent influx of neutrophils and 
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monocyte-macrophages.1 The increased 
cytokine production and associated 
CRP may cause the condition called as 
“cytokine storm” which presents in a 
vicious cycle fashion and may cause 
more damage to the cells of the lungs. 
Initial increment of CRP was suggested 
to be used to predict severe cases.47
Despite their purpose to fight off the 
invading pathogen, the inflammatory 
cells can mediate further tissue 
damage by inciting lung epithelial 
and endothelial apoptosis via Fas-Fas 
ligand (FasL) or Tumor necrosis factor 
(TNF)-related apoptosis-inducing-
ligand-Death Receptor 5 (TRAIL-DR5)-
dependent mechanisms.48 Apoptosis 
compromises the lung microvascular 
and alveolar epithelial cell barriers 
resulting in vascular leakage and 
alveolar edema. Indeed, pathologic lung 
examination of two COVID-19 patients 
with adenocarcinoma revealed diffuse 
alveolar damage (DAD). Pulmonary 
edema, proteinaceous and fibrin 
exudates, mononuclear inflammatory 
cell infiltration with multinucleated 
giant cells, alveolar wall thickening with 
pneumocytes hyperplasia and fibroblast 
proliferation, without prominent 
hyaline membrane were observed in 
both patients. The absence of clinical 
symptoms of pneumonia indicates these 
pathological findings may depict early 
lung abnormality of COVID-19.49 Later on 
the DAD could lead to acute respiratory 
distress syndrome (ARDS), in which 
respiratory failure is characterized by the 
rapid onset of widespread inflammation 
in the lungs and subsequent fatality.50At 
this late stage, extensive fibrin 
deposition (fibrosis) and alveolar 
collapse occur.51Similar mechanisms 
manifested in lung immunopathology 
were also shown in mouse models of 
SARS-CoV infection.23The ‘cytokine 
storm’ also occurs in SARS-CoV-2 
infection particularly in severe 
cases.19,52Furthermore, the cytokines can 
spill over to the circulation, resulting 
in systemic sepsis and multi organ 
dysfunction and failure53 including 
myocardiac complication reported in 
many fatal cases.
TABLE 1. Innate immune response against SARS-CoV-2
Immune responses to 
SARS-CoV-2 infection
Action Dysregulation in severe cases of COVID-19
Detection by PRRs 
(including TLR7, TLR8, 
RIG-I, MDA5)
Induces NF-κB and MAPK 
pathways to activate type I 
interferon system and other pro-
inflammatory cytokines.
Coronavirus avoids PRRs detection by 
concealing its RNA inside replication 
organelles; adding cap structure 
or methylating its RNA; activating 
endonuclease to degrade its own RNA; 
halting host’s translation process; 
destructing host’s mRNA;or inhibiting 
stress granules formation.a,34-39
Type I interferon Has antiviral activity. IFN-
stimulated genes inhibit 
virus entry, replication and 
dissemination. 
Coronavirus prevents phosphorylation 
and nuclear translocation of IFN-related 
trancription factor, inhibit activation of 
IFN system.a,41
Enhances NK cells activity to 
kill infected cells and to secrete 
IFN-γ; promotes macrophage 
phagocytosis activity and 
pro-inflammatory cytokines 
production; stimulates DC 
maturation and antigen 
presentation to T cells; increases 
MHC I surface expression
Delayed or impaired antiviral response 
of type I IFN results in uncontrolled viral 
replication and dissemination.
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Natural Killer (NK) cells NK cells target and kill virus-
infected cells and produce type I 
interferon cytokines.
Decrease IFN-γ and increase NKG2A 
expression in NK cells, indicating 
functional cells exhaustion and impaired 
virus-killing activity.52
Macrophages/monocytes Macrophages infiltrate infected 
sites; phagocytose apoptotic 
virus-infected cells; mediate 
antibody-dependent cell 
cytotoxicity; and secrete pro-
inflammatory cytokines.
Hyper-influx of macrophages-monocytes 
into the lung that leads to apoptosis of 
lung epithelial and endothelial cells 
and tissue damage. Coronavirus also 
can infect macrophages, rendering it 
malfunction.a,42,43,48
Pro-inflammatory cyto-
kines
Increase secretion of IL-1R, 
IL-6, TNF-α, IL-8, IP-10, MCP1, 
MIP-1a upon virus infection to 
recruit neutrophils, monocytes-
macrophages, and T cells to 
infected site and augment their 
antiviral action.
Exaggerated release of pro-inflammatory 
cytokines or cytokine storm occurs; leads 
to further tissue damage, ARDS, systemic 
sepsis, and multi organ dysfunction.19,50
Neutrophil in tissue 
inflammation
Neutrophils migrate to infected 
sites; phagocytose apoptotic 
virus-infected cells; and secrete 
pro-inflammatory cytokines to 
recruit more immune cells.
Neutrophilia; with hyper-influx of 
neutrophils into the lung that leads to 
tissue damage.19,48,50
aObserved in SARS-CoV or MERS-CoV, however, no information available for SARS-CoV-2 yet.
ARDS, acute respiratory distress syndrome. DC, dendritic cells. IFN-γ, interferon-gamma. IL-1R, 
interleukin-1 receptor. IL-6, interleukin-6. IL-8, interleukin-8. IP-10, interferon gamma-induced protein 
10. MAPK, mitogen‐activated protein kinases. MCP1, monocyte chemoattractant protein 1. MDA5, 
melanoma differentiation-associated gene 5. MIP-1a, macrophage inflammatory protein 1-alpha. MHC 
I, major histocompatibility complex class I. NF-κB, nuclear factor-kappa beta. NK, natural killer. NKG2A, 
natural killer group 2 member A. PRRs, pattern recognition receptors. RIG-I, retinoic-acid-inducible gene 
I. TLR7, Toll‐like receptor-7. TLR8, Toll‐like receptor-8. TNF-α, tumor necrosis factor-alpha
Besides causing massive apoptosis 
and tissue injury, this ‘cytokine storm’ 
can diminish T cells response via 
TNF-mediated apoptosis. In patients 
with COVID-19, a more pronounced 
lymphopenia is observed in fatal 
cases,52,54 suggesting that COVID-19 may 
damage T lymphocytes. Furthermore, 
the numbers of CD4+ and CD8+ T cells 
were decreased,50,52,54 with naïve CD4+ T 
cells count elevated but that of memory 
CD4+ T cells decreased.52 Considering 
that the differentiation of naïve T 
cells into effector and memory cells is 
fundamental for the immune response, 
the higher naïve to memory ratio of 
CD4+ T cells in severe cases indicates 
an impaired and unbalanced immune 
response caused by SARS-CoV-2 infection. 
In addition, the production levels of 
IFN-γ by CD4+ T cells, CD8+ T cells, and NK 
cells tend to be lower.54 The production 
of IFN-γ is essential for resistance against 
infection of various pathogens and IFN-γ 
was reportedly able to inhibit viral 
replication of SARS-CoV.55 Lower IFN-γ 
levels in severe cases of COVID-19 might 
reflect the host’s inability to fight off 
the virus which increases the likelihood 
of fatality. Strong T cells’ responses are 
significantly correlated with higher 
neutralizing antibody, while more serum 
TH2 cytokines (IL-4, IL-5, IL-10) were 
detected in the fatal group of SARS-CoV.26
Another interesting effect that SARS-
CoV-2 infection has on T lymphocytes 
is that it may induce T cells exhaustion. 
Lymphopenia was common in patients 
with SARS-CoV-2 (72%) as well as in 
acute phase of patients with SARS-CoV 
(~80%).12,21 At the infection onset, it was 
indicated by the drainage of lymphocytes 
into the infected tissue but in later 
stages it indicates the impairment of 
immune system. Beside the decline in 
T cells number, COVID-19 patients also 
showed increased expression of natural 
killer group 2 member A (NKG2A) in 
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CD8+ T cells and NK cells.54 NKG2A is 
an inhibitory receptor, which induces 
immune cells exhaustion in chronic 
viral infection.56 Its increased expression 
in CD8+ T cells suggests functional 
exhaustion of cytotoxic lymphocytes in 
COVID-19 patients. The elevated level of 
interleukin-10 (IL-10) in severe cases of 
COVID-19 supports this plausible notion. 
Although there is no evidence concerning 
the ability of IL-10 to increase NKG2A 
expression, however, IL-10 regulates 
inhibitory receptor (e.g. Programmed 
cell-death protein 1; PD-1) expression 
in CD8+ T cells57 and induces sustained 
PD-1 expression and T cells exhaustion,58 
leading to a suppressive environment 
that prevents viral clearance.
Humoral immune response against 
SARS-CoV-2 may also contribute to the 
severity of the disease. COVID-19 patients 
with higher IgG levels tend to have more 
severe disease symptoms compare to 
those with lower IgG level.59 It has been 
proposed that IgG humoral response 
may contribute to tissue damage by 
a mechanism known as antibody-
dependent enhancement (ADE). ADE 
has been confirmed in multiple viral 
infections.59 ADE occurs when antiviral 
neutralizing antibodies (Nab) cannot 
fully neutralize the virus. Instead, the 
virus-NAb complexes bind to the Fc 
Receptor (FcR) in macrophages, leading 
to viral endocytosis and infection of 
macrophages. This leads to persistent 
virus replication and exuberant pro-
inflammatory cytokines signaling which 
eventually causes acute fatal lung injury, 
as has been observed in patients with 
SARS-CoV infection.60
The impaired immune system in 
severe cases may increase the risk for 
bacterial co-infection. A study in China 
reported that 10% of the COVID-19 
severe cases suffered from secondary 
infection.19 Tissue damage, exuberant 
inflammatory cell influx observed 
in cytokine storm phenomenon may 
render the pro-inflammatory response 
inadequate, e.g. lymphocytes recruitment 
to new infected site and macrophages 
phagocytosis capacity, when challenged 
with a bacterial pathogen, while 
enhancing bacterial entry or adherence 
to host’s cell.61
TABLE 2. Adaptive immune response against SARS-CoV-2
Immune responses 
to SARS-CoV-2
Action Dysregulation in severe cases of COVID-19
Antigen presentation 
by dendritic cells
Respiratory dendritic cells engulf 
viral antigen; migrate to lymph 
nodes and presented viral antigen 
to naïve T cells.
Coronavirus infects DC and render it 
malfunction; downregulates its MHC I and II 
expression, impairing antigen presentation to 
naïve T cells.a,42,43
Cytotoxic T cells 
(CTL)
Activated CTL migrate to lung. CTL 
target virus-infected cells and induce 
their apoptosis by the cytotoxic 
granule release and production of 
TNF-α and IFN-γ.
Severe lymphopenia and low CD8+T cells count 
with increased NKG2A and decreased IFN-γ 
expression, indicating impaired T cells killing 
capacity and their functional exhaustion.12,48,50,52
T helper 1 (TH1) Secretes IFN-γ and TNF-α; activates 
macrophages and augment their 
phagocytosis activity.
Severe lymphopenia and low CD4+ T cell 
count with decrease IFN-γ expression. CD4+ 
T cell depletion is associated with reduced 
pulmonary infiltration of lymphocytes and 
cytokines production.a,12,48,50,52
T helper 2 (TH2) Secretes IL-4, IL-5, IL-13 which 
primarily induces plasma cells to 
produce virus-specific antibody.
Severe lymphopenia with low CD4+ T cell count. 
Low TH2 can result in decrease production of 
neutralizing antibodies.a,12,48,50,52
T helper 17 (TH17) Release pro-inflammatory 
cytokines.
High CCR6+ TH17, further exacerbating 
inflammation by downregulating Treg cells, 
promoting neutrophil migration.48
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Regulatory T cells 
(Treg)
Suppress immune responses, 
secrete anti-inflammatory cytokines 
(IL-10, TGF-β).
Low Treg count, may exacerbate inflamma-
tion.50
Lymphocytes in 
tissue inflammation
Effector lymphocytes migrate 
into site of infection lead to mild 
lymphopenia.
Lymphopenia. Mononuclear cells infiltration 
with many lymphocytes in the lung. Apoptosis 
of lymphocytes. Atrophy of spleen and lymph 
nodes were reported in autopsy.12,47,48,50
IgM Neutralizes the virus on the early 
phase of the disease.
Low IgM level, indicating ineffective virus 
containment on the early phase of the disease, 
leads to unchecked virus replication.
IgG Neutralizes the virus, activates 
complement system & antibody-
dependent cellular cytotoxicity.
High IgG level. Antibody can leads to immune 
enhancement resulting in infection of 
macrophages; persistent virus replication 
and exuberant pro-inflammatory cytokines 
production.
IgA Neutralizing antibody in mucosa, 
can be detected in plasma. IgA 
secreting plasma cells is found in 
plasma.
Not much data, most probably in lower level 
compared to mild cases.
Memory cells Memory B cells produce long-
lived circulating virus-specific 
neutralizing Ab.
Low naïve to memory T cells ratio, suggesting 
impaired memory cells induction or 
differentiation.50
Memory CD8+ T cells effectively 
produce IFN-γ, TNF-α, IL-2 to 
prevent viral replication and 
alveolar damages.
aObserved in SARS-CoV or MERS-CoV, however, no information available for SARS-CoV-2 
yet.
CCR6, C-C chemokine receptor 6. CTL, cytotoxic T lymphocytes. DC, dendritic cells. 
IFN-γ, interferon-gamma. IgA, immunoglobulin A. IgG, immunoglobulin G. IgM, 
immunoglobulin M. IL-2, interleukin-2. IL-4, interleukin-4. IL-5, interleukin-5. IL-10, 
interleukin-10. IL-13, interleukin-13. MHC I, major histocompatibility complex class 
I. MHC II, major histocompatibility complex class II. NKG2A, natural killer group 2 
member A. TNF-α, tumor necrosis factor-alpha. TGF-β, transforming growth factor-beta. 
Treg, regulatory T cells.
Host factors that influence immune 
responses against SARS-CoV-2
China, Southern Europe and 
American East Coast took turns as 
areas with the highest number of cases 
during the course of the pandemic. In 
several regions and countries, certain 
races and foreign-born individuals were 
disproportionately affected. Whether 
genetic and epigenetic factors are 
involved in increasing the morbidity 
and mortality risks in the most severely 
affected areas, needs further study. The 
1918 H1N1 pandemic reported high 
mortality in indigenous communities 
in Australia, Alaska and South America 
that may be due to genetic factors or 
lack of cross-immunity.61 Currently, 
temperature and humidity as well as 
frequency of traveling and migration, 
population density and social 
background are considered as crucial 
factors in the SARS-CoV-2 spreading.62,63 
Increasing reports have discussed 
older age, male and comorbidity as 
risks factors for COVID-19. However, 
detailed demographic data for COVID-19 
cases are not yet available. Most of the 
government agencies have only reported 
the number of active cases, recovered 
and death cases without specific case 
characteristics.
From China, the first epicenter of 
the pandemic, reports confirmed that 
older people are more susceptible to 
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SARS-CoV-2 than the younger group.12,62 
Children and adolescents are less 
susceptible to SARS-CoV-2, probably 
due to the low expression of ACE2.64The 
median of the patients’ ages ranged from 
41 to 57 year.  Old age is known as a 
risk factor for infection as reported for 
SARS-CoV infection65 as well as a study in 
non-human primate infected with SARS-
CoV.66 Prior to infection, CD8+ T cells and 
B cells were lower in aged monkeys and 
after infection CD8+ T cells and B cells 
responses were significantly reduced in 
the aged host.66 A study of mice models 
of West Nile Virus infection found 
the virus also predominantly infects 
the old population. Malnutrition that 
occurs more frequently in elderly67 may 
enhance vulnerability to infection during 
aging. The IgM and IgG response are 
commonly impaired and this was linked 
to delayed germinal center formation in 
the draining lymph node.68
Older patients showed severe 
symptoms at hospital admission.62 Most 
of the patients in China that died were 
older than 50 years with median age of 
70 years old.69 European countries also 
reported that the death rate was higher 
among senior citizens more than 70 
years old. Worldometer in April 14, 2020 
reported the data from New York that 
47% of the patients that died were more 
than 70 years old. Despite the higher 
rate of comorbidities found in older 
individuals, the dysregulated immune 
response may contribute to the more 
severe effects in older individuals. This 
may be due to lower number of Treg, 
aberrant microbiota composition, and 
higher proportion of inflammatory cells 
during aging. 
Many reports from SARS-CoV-2 
infection in China revealed that50–
75% admission to the hospitals were 
male.12,19,62,67 Moreover, more men died 
with COVID-19 compared to women.69 
The Guardian, April 16, 2020 edition 
reported that the number of men who 
died of COVID-19 in England and Wales 
was about twice the rate of women.70 In 
New York, Worldometer at April 14, 2020 
revealed that male patients comprised 
61% of the mortality from COVID-19 and 
even higher up to 72% in patients without 
underlying conditions.71 The data are 
in accordance with the predominantly 
male patients reported in previous 
case mortality rates of SARS-CoV72 and 
MERS-CoV.73 Despite social factors such 
as working outside home, healthcare 
seeking behavior, smoking habit and 
medical and biological factors such 
as higher proportion of comorbidities 
e.g. hypertension and diabetes as well 
as higher expression of ACE receptors 
that are correlated with males, some 
important aspects of immunological 
background still contribute to the higher 
proportion and severity of male patients 
with COVID-19.74
The difference in immune response 
between sex was reported by many 
reports.Females have lower susceptibility 
to infection partly due to several genes 
encoded in X chromosomes. One of 
the genes is TLR-7 that detects viral 
RNA, resulting in higher production of 
antiviral substance type I IFN.75 Females 
have higher expression of TLR-7 that is 
partly mediated by estrogen signaling. 
Male mice were more susceptible to 
SARS-CoV infection compared with 
age-matched females and the degree 
of sex bias to SARS-CoV infection 
increased with advancing age.76 The X 
chromosome influences the immune 
system’s response against viral infection 
by acting on many other genes, including 
TLR-8, CD40L and CXCR3 which can be 
over-expressed in women. Infection 
of mice with H1N1 induced antibody 
responses, CD4+ T cells and CD8+ T cells 
memory responses that were greater in 
females than males.76
Males tend to have higher 
proinflammatory profiles than females, 
hence increasing the risk of excessive 
inflammation in severely affected cases. 
Many regulatory proteins in the immune 
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system such as FOXP3, the transcription 
factor for Treg are encoded in X 
chromosomes. In women the production 
of inflammatory IL-6 after viral infection 
is lower than in males and is often 
correlated with a better longevity. A mice 
study on SARS-CoV infection showed 
a persistent increase of inflammatory 
monocytes and neutrophils in SARS-CoV 
infected male mice but not in female mice. 
The estrogen signaling in female mice is 
proposed to reduce the accumulation 
and function of macrophages in the 
mice lungs and have a protective effect 
against viral infection.76 These data are 
in accordance with several reports that 
showed sexual dimorphism in immune 
response to COVID-19 infection.
Several comorbidities that increase 
COVID-19 severity has been reported such 
as hypertension62 and diabetes77 that are 
partly based on the patients’ medication 
or condition that can upregulate ACE2 
expression.78 Higher expression of ACE2 
not only permits more viral entrance but 
is also augmenting immune response and 
proinflammatory cytokine production, 
which correlated with fatal cases.79 
The impact of the unhealthy Western 
diet that leads to inadequate immune 
response and chronic inflammatory 
state in COVID-19 pathology has also 
been discussed recently.80 The complex 
pathogenesis of COVID-19 still needs to 
be elucidated, in which the effect of SARS-
CoV-2 in erythrocytes and components of 
blood coagulation in addition to immune 
responses, plays an important role in the 
process. Several interesting observations 
such as coronaviruses have not been 
shown to cause a more severe disease 
in immunosuppressed patients,81 need 
more confirmation in the future.
Immunological memory and herd 
immunity
Reappearance of highly contagious 
viral infections such as SARS-CoV-2 
is a crucial public health problem. 
Immunological memory is important for 
the effective response against pathogens 
that have been encountered previously. 
It generates immediate protection and 
greater magnitude of immune response. 
Whether memory T cells response is 
sufficient to protect from re-infection of 
SARS-CoV-2 needs further study. In SARS-
CoV-2 infection, the detection of specific 
IgG against SARS-CoV-2 in the patients’ 
sera28 provides early evidence for 
immunological memory. However, since 
the COVID-19 pandemic is still ongoing, 
data on the time-period of antibody peak 
level and the duration of the antibody 
detectability are not yet available on a 
large scale.
Neutralizing antibodies against S 
protein protect the susceptible host from 
lethal infection. However, several studies 
reported that anti-SARS-CoV antibody 
response is short-lived in patients who 
have recovered from SARS-CoV.23 IgG 
titer peaks at 3-4 months. It remains 
detectable 2 years after infection 
and starts to decline after 2 years.31 
Immunological memory to one type of 
coronavirus may not provide protection 
against another type of coronavirus as 
shown in the absence of cross-reactivity 
of CD8+ T cells responses against SARS-
CoV with MERS-CoV.82
Few reports are available on memory 
T cells in SARS-CoV-2 infection. After the 
SARS-CoV outbreak, SARS-CoV-specific 
memory T cells had been screened 
in SARS convalescent patients.32 All 
memory T cells detected were directed 
at SARS-CoV spike (S), membrane (M) 
or nucleocapsid (N) protein. These 
memory T cells were found to last up 
to 6 years after infection32 with most 
of them identified as polyfunctional 
central memory T cells.26 Re-infection 
with SARS-CoV has demonstrated the 
protection provided by memory T 
cells. In immunized mice challenged 
with lethal doses of SARS-CoV, its virus-
specific memory CD8+ T cells efficiently 
produced cytokines including IFN-γ, 
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TNF-α, IL-2 and cytolytic molecules, e.g. 
granzyme B. These responses prevented 
extensive viral replication and alveolar 
damages.23 Given the short-lived 
duration of antibody-specific-SARS-CoV, 
the long-lived memory T cells and its 
proven protection upon re-infection is of 
considerable significance. However, it is 
worth noting that a decrease in memory 
T cells count in SARS-CoV-2 infection 
with high naïve to memory T cells ratio52 
might indicate impaired memory T cells 
induction.
Even though many uncertainties 
remain concerning immunological 
memory towards SARS-CoV-2, several 
countries endorse the idea of herd 
immunity. The common notion in 
herd immunity is that exposure of the 
virus to the population may induce 
immunological memory for most 
people. As more and more people 
become immune to the virus, an infected 
individual has less and less chance of 
coming into contact with an individual 
susceptible to infection. Finally, herd 
immunity becomes pervasive which at 
that point, the number of cases will start 
to decline. If herd immunity is achieved, 
even in the absence of measures designed 
to slow or contain transmission, the virus 
will be contained.83
However, there are many concerns 
regarding herd immunity in SARS-CoV-2. 
One concern has to do with the duration 
of the immunological memory and re-
infection. Recently, SARS-CoV-2 patients 
who have been declared recovered by 
two negative tests for the virus later 
tested positive again.84 If these cases 
were indeed re-infection, it would cast 
doubt on the immunological memory 
developed by the infected individual. 
Another concern is the possibility of 
immune enhancement caused by the 
infection.59 If immunity against SARS-
CoV-2 leads to exacerbation of the 
infection rather than prevention of it, 
more fatalities will emerge. Whether 
the virus is mutating over time is also 
an issue that needs to be addressed. If 
the virus is mutating even at a slow rate, 
what those changes will do is a bigger 
question. The mutations could make the 
virus more easily transmitted or better at 
evading our immune system. The main 
question regarding herd immunity in this 
current pandemic is what percentage of 
the population is needed to get infected 
to achieve herd immunity. As of today, 
it is very likely that the number of 
COVID-19 cases is underestimated. Also, 
considering the severity of the disease 
and its case fatality rate that varies 
among many countries, the idea of herd 
immunity may not be appropriate for 
the current situation.
Preventive vaccination and 
immunotherapy against coronavirus
Considering the significant protection 
conferred by memory cells and the fact 
that COVID-19 is still spreading globally 
with no specific treatment yet available, 
it is worth noting that probably vaccines 
offer the best options to control the 
current pandemic. By vaccination, 
those who have not been infected by 
SARS-CoV-2 will have antibodies which 
will readily generate protection with 
greater response against SARS-CoV-2. 
In addition, vaccination also provides 
protection against re-infection for those 
who have recovered from SARS-CoV-2 
infection. The immediate availability of 
SARS-CoV-2 genomic sequence5 and the 
recent mapping of SARS-CoV-2 spike (S) 
protein85 may lay the foundation for more 
rapid development of a specific vaccine. 
From studies on SARS-CoV vaccines, the 
S protein on the surface of the virus is an 
ideal target for a vaccine.86
According to the most recent 
report, currently 73 SARS-CoV-2 vaccine 
candidates are undergoing development 
at preclinical stages and 5 others are 
entering clinical trials in humans. These 
5 vaccine candidates include mRNA-1273 
(NCT04283461/Moderna), Ad5-nCoV 
(NCT04313127/CanSino Biologicals), 
INO-4800 (NCT04336410/Inovio), LV-
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SMENP-DC (NCT04276896/Shenzhen 
Geno-Immune Medical Institute), and 
pathogen-specific aAPC (NCT04299724/
Shenzhen Geno-Immune Medical 
Institute). As of mid-March 2020, mRNA-
1273 (Moderna) and Ad5-nCoV (CanSino 
Biologicals) have become two of the 
first SARS-CoV-2 vaccines to be tested 
on humans.87 Significant breakthroughs 
in vaccine technology have provided 
more vaccine development platforms. 
The platforms used in the development 
of SARS-CoV-2 vaccine range from RNA 
vaccine, DNA vaccine, viral vector-based 
vaccine, recombinant protein vaccine, 
live attenuated vaccine, and inactivated 
vaccine. Among these platforms, RNA 
vaccine design gives flexibility on 
antigen manipulation and improves 
protein translation efficiency which 
can induce a more robust immune 
response.88 Additionally, RNA vaccine 
is more rapid and less expensive than 
traditional vaccines88 which would give 
some advantages and benefits especially 
during the pandemic situation as it is 
today.
Although there is urgency to 
provide a vaccine rapidly due to the 
current pandemic, governments and 
pharmaceutical companies need to 
ensure the safety of the vaccine. Lessons 
need to be learned from the experience 
of developing a vaccine for SARS-CoV. 
Several vaccines for SARS-CoV have 
been tested in animal models. Most of 
these vaccines protected animals from 
the challenges of SARS-CoV, but, many 
did not induce sterilizing immunity. 
In some cases, vaccination resulted in 
complications89 or led to enhancement of 
the disease.90 Up to this moment, there is 
no vaccine for SARS-CoV available.
Another aspect that needs to be 
considered for a more effective SARS-
CoV-2 vaccine development is the 
decline of antibody response over time. 
Coronavirus infection does not always 
induce long-lived antibody response. An 
individual can be re-infected with the 
same virus after an extended period of 
time. In individuals that recovered form 
SARS-CoV infection, antibody titer starts 
to decline 2 years after illness onset.31 
Recently, reports emerged that SARS-
CoV-2 re-infection occurs days after 
recovery.84 Thus, a SARS-CoV-2 vaccine 
will need to tackle this issue to provide 
protection in case the virus becomes 
endemic and causes recurrent seasonal 
epidemics.
SARS-CoV-2 infection causes more 
severe morbidity and more mortality 
among older individuals. Therefore, it 
will be important to develop vaccines 
that offer protection to this population. 
Unfortunately older individuals typically 
respond less well to vaccinations because 
of immune senescence.91 This is another 
concern that needs to be addressed for 
SARS-CoV-2 vaccine development.
One of the simple therapeutic 
modalities for severe cases of COVID-19 
is convalescent plasma. It has been 
used during the SARS outbreak92 and 
is currently used to treat COVID-19 
patients.93 Other treatments that have 
been used during this ongoing pandemic 
are intravenous immunoglobulin 
(IVIG)94 and intravenous injection of 
mesenchymal stem cells.95 Since it is 
very likely that the ‘cytokine storm’ 
is the main cause of fatal cases of 
COVID-19, it is worth considering the use 
of a neutralizing antibody against pro-
inflammatory cytokines involved in the 
pathogenesis of COVID-19. One of those 
is tocilizumab, a monoclonal Ab against 
IL-6R. In China, tocilizumab has been 
approved to treat COVID-19 patients with 
pneumonia and elevated IL-6 levels.96 
Corticosteroid is another medication 
used to suppress inflammatory responses 
in COVID-19 patients.12,19 However, the 
lack of proven benefit in COVID-19 cases 
should render health care workers to 
be cautious on its usage. The strategy to 
suppress immune responses in severe 
cases is challenging as the main immune 
component that should be inhibited 
is currently not yet clearly identified. 
The timing to start the therapy without 
compromising the beneficial host 
defense is another question that needs 
an immediate answer. Furthermore, 
while the aforementioned therapies are 
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currently used to treat a limited number 
of COVID-19 patients, evaluation and 
study on their efficacy are still required.
Heterologous immunity is thought 
to be a contributing factor that reduces 
severity of an infection in any age. 
Exposure to one pathogen may alter the 
subsequent innate and adaptive immune 
responses to a different pathogen. It 
will be interesting to study whether 
history of infectious diseases alters 
the vulnerability to suffer from severe 
COVID-19 via the heterologous immunity 
mechanism. The number of cases in 
some countries that has nationwide 
Bacille-Calmett Guerin (BCG) vaccination 
program, are less numerous than other 
countries with no BCG vaccination 
program such as European countries, 
leading to the idea that BCG vaccination 
may give some protection from SARS-
CoV-2 infection. This idea is being tested 
with two clinical trials, although last 
year a review showed some evidence 
against it.97
Some alternative treatments 
related to immune function have 
been proposed for COVID-19 patients. 
Many doctors recognize the role of 
positive thinking, praying, meditation 
in the outcome of diseases, including 
COVID-19. Preliminary studies shows a 
beneficial impact of vagal stimulation, 
a method that activate autonomic 
nervous system to suppress immune 
function on the recovery of COVID-19 
patients.98 Herbal medicine has also 
been used for COVID-19 treatment,99 yet 
the efficacy as well as its mechanism of 
action in the immune system, if any still 
need more study. Any herbal medicine 
that may balance immune responses, 
activate appropriate responses against 
SARS-CoV-2 while preventing excessive 
inflammation as discussed for the 
famous Chinese herbal remedy called 
Astragalus100 may be beneficial in the 
fight against this disease. The prospect 
of using Indonesian herbal medicine for 
balancing immune responses also needs 
to be investigated due to the region’s 
biological diversity.
The aftermath
While currently not and hopefully 
never considered the epicenter of the 
outbreak, Indonesia is the 4th largest 
population with a large variability of 
ethnic and socioeconomic backgrounds, 
hence increased vulnerability to any 
contagious pathogens. As of 28th of April 
2020, the WHO database recorded 9096 
confirmed cases in Indonesia, including 
765 deaths. The mortality rate from 
COVID-19 in Indonesia is among the 
highest in the world. High incidence of 
infectious diseases and the rise of non-
communicable diseases as well of the 
large smoking population in Indonesia 
may contribute to dysregulation of 
immune responses. Whether those 
factors lead to higher incidence of 
severe cases and mortality rate of 
COVID-19 in Indonesia remains to be 
elucidated. Another important issue 
in the Indonesian fight against SARS-
CoV-2 is the late development of a rapid 
serological test. Many believe that due to 
the lack of proper test, the true infection 
and death rate are higher that the 
reported data. Development of stronger 
infrastructure and increased pools 
of personnel for basic research and 
reduction of dependency on imported 
medical reagents need to be strategically 
planned.
When will the current global 
pandemic end? One projection proposed 
that we still need some form of social 
distancing until 2022 and should be ready 
for resurgence of the outbreak in 2024.101 
Keeping all of previous discussion in 
mind, serological studies are needed to 
determine the duration of immunity 
to SARS-CoV-2. The current practice of 
using rapid tests as COVID-19 infection 
screening and discussion of using 
quantitative methods was reviewed 
recently.2
A study in China reported that 
autoantibodies were found in SARS-
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CoV-2 patients.102 Infection is considered 
as a risk factor for autoimmune diseases 
via molecular mimicry or bystander 
activation. On the other hand, infection 
may inhibit self-reactive T cells via 
activation of immune regulation to 
balance the activation of immune system 
against the pathogen as has been shown 
in mice infected with coronavirus.103 
Whether there is any effect of the current 
pandemic to the rate of autoimmune 
diseases and other conditions related 
to self-reactive immune components 
remains to be elucidated. The hygienic 
behavior such as the use of hand 
sanitizer, washing hands with soap 
frequently and showering after arriving 
home from outdoor activities as well as 
the spraying of disinfectant may disrupt 
immune regulation via alteration of 
microbiome profile with several health 
consequences, including obesity.104
Healthy diet, vitamin 
supplementation, sufficient hours for 
sleeping at night, and regular exercise 
are considered as protective measures 
from the development of severe 
symptoms by strengthening the immune 
system. Many efforts have been taken to 
promote a healthy life style campaign in 
local and social media while people are 
staying at home during the pandemic. 
Continuation of the good habits obtained 
during the pandemic may provide 
benefits for stronger immune function 
and general health in the future. On the 
other hand, uncomfortable feelings while 
wearing mask and protective equipment, 
reduced physical activity and stressful 
situations during social distancing as 
well as socioeconomic problems related 
to it, may impose negative consequences 
for immune system leading to various 
disorders.105 These changes of lifestyle 
and their impact and long-term effects on 
the immune system warrant subsequent 
investigation.
TABLE 3. Immunological studies relevant to COVID-19 in Indonesia
Studies on Indonesian COVID-19 cases.
Immunological profile of Indonesian COVID-19 patients, the correlation with disease severity and which host 
factor contributes most in severe cases.
The effect of comorbidities (infection and non-infection) to the immunological profile related to disease 
progression.
Possible alternative route of infection (e.g. gastrointestinal tract, central nervous system) and correlated 
immune response in designated organs.
Evaluation of serological-based test used in Indonesia during COVID-19 pandemic (sensitivity, specificity).
Methods of serological screening: developing Indonesian-based test (rapid test, ELISA based test).
Evaluation of the current immunotherapy and development of novel immunotherapeutical agent, including 
Indonesian herbal medicine.
Do we achieve herd immunity? How many cases of asymptomatic COVID-19 can be found? Which host factor 
contributes most to appropriate immune response in the asymptomatic cases?
Immunological profile of COVID-19 survivors: How long does the protective antibody last? Cellular immune 
response of the memory cells. Possible alteration in the epigenetic status (trained immunity).
Study on the prospect of vaccine development suitable for common type of SARS-CoV-2 in Indonesia.
Study on the effect of changing lifestyle during and after the pandemic on immune-related problem.
Effect of adopted lifestyle and stress during social distancing on immunological profile, especially in individuals 
with high risk for severe COVID-19 (elderly, male, hypertension, allergy, autoimmune, etc.).
Correlation of “super-hygienic” lifestyle, microbiota diversity and immunological profile in Indonesian 
population.
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The profound effect COVID-19 
pandemic has on all aspect of life has 
ignited the global scientific community 
to work and team up to uncover more 
about this disease and discover the best 
strategy to overcome it. The same should 
be happening in Indonesia as currently 
we also dealing with the consequences 
conferred by the pandemic. Wide array 
of research topic in immunology field 
relevant to the situation in Indonesia 
is still waiting to be explored (Table 3). 
The more knowledge we have about this 
disease, the more chances we have to 
defeat it.
CONCLUSION
Innate and adaptive immune 
responses may keep SARS-CoV-2 at 
bay and prevent severe symptoms. 
However, several host factors such as 
genetic and epigenetic factors from old 
age, male, history of previous infection, 
and comorbidities as well as the immune 
evasion mechanism of the virus may 
influence the immune responses leading 
to severe and fatal cases.
The highly contagious nature of the 
virus prompts swift action to contain it 
from spreading further. Vaccines, though 
needing time for proper development, 
might offer the best chance to fight off the 
virus especially if it becomes a situation 
involving recurrent seasonal epidemics. 
However, for now, physical distancing 
combined with healthy lifestyle provide 
the best options to keep the virus in 
check.
As the pandemic situation continues 
developing, the best available scientific 
evidence should be used to guide 
future research aimed to uncover more 
about the disease, discover the best 
diagnostic, therapeutic and intervention 
strategies, curb the worst possible 
outcomes and prepare for the likely next 
pandemic. Thus, research collaboration 
between governments, international 
organizations, and the private sector 
is urgently required. Real-time sharing 
of scientific information about the 
virus, disease pathogenesis, and 
human’s immune response will lead to 
advancement of the knowledge needed 
to overcome the many challenges from 
the current pandemic.
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